1887
Volume 2021, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease (COVID-19), has undergone numerous mutations since its initial identification, leading to challenges in controlling the pandemic. Till date, several variants of concern have been identified. However, currently, the Delta variant (B.1.617.2) is the most dreaded one owing to its enhanced transmissibility and increased virulence. In addition, this variant can potentially facilitate fusion of the spike protein to cells or inhibit antibodies from binding to it. In this commentary, we have simplified the complexity of the nomenclature of variants related to COVID-19, concentrating on the Delta variant including its transmissibility, response to vaccines, and prevention.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2021.49
2021-10-05
2021-10-26
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2021/3/qmj.2021.49.html?itemId=/content/journals/10.5339/qmj.2021.49&mimeType=html&fmt=ahah

References

  1. Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and Novel Therapeutics against coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2021 June 29:2021 Jan–. PMID: 34033342.
    [Google Scholar]
  2. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature 2021; 595:(7865):17–18. doi: 10.1038/d41586-021-01696-3 .
    [Google Scholar]
  3. Center for Disease Control and Prevention. About variants of the virus that causes COVID-19. Available from https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html. Accessed August 1, 2021.
    [Google Scholar]
  4. Sender R, Bar-On YM, Gleizer S, et al. The total number and mass of SARS-CoV-2 virions in an infected person [preprint]. medRxiv 2020:2020.11.16.20232009. doi: 10.1101/2020.11.16.20232009 .
    [Google Scholar]
  5. Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn 2021; 39:(10):3787–3792. doi: 10.1080/07391102.2020.1767691 .
    [Google Scholar]
  6. Hendaus MA, Jomha FA. mRNA vaccines for COVID-19: A simple explanation. Qatar Med J 2021; 2021:(1):07. doi: 10.5339/qmj.2021.07 .
    [Google Scholar]
  7. Hendaus MA, Jomha FA. Covid-19 induced superimposed bacterial infection. J Biomol Struct Dyn 2021; 39:(11):4185–4191. doi: 10.1080/07391102.2020.1772110 .
    [Google Scholar]
  8. Hendaus MA, Jomha FA. From COVID-19 to clot: the involvement of the complement system [published online ahead of print, October 16 2020]. J Biomol Struct Dyn 2020:1–6. doi: 10.1080/07391102.2020.1832919 .
    [Google Scholar]
  9. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020; 41:(9):1141–1149. doi: 10.1038/s41401-020-0485-4 .
    [Google Scholar]
  10. Kang L, He G, Sharp AK, et al. A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation [published online ahead of print, July 7 2021]. Cell 2021; S0092-8674:(21):00833–00833. doi: 10.1016/j.cell.2021.07.007 .
    [Google Scholar]
  11. WHO. Tracking SARS-CoV-2 variants. Available from https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed August 2, 2021.
    [Google Scholar]
  12. Konings F, Perkins MD, Kuhn JH, et al. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat Microbiol 2021; 6:(7):821–823. doi: 10.1038/s41564-021-00932-w .
    [Google Scholar]
  13. Burrell CJ, Howard CR, Murphy FA. Classification of viruses and phylogenetic relationships. Fenner White's Med Virol 2017:15–25. doi: 10.1016/B978-0-12-375156-0.00002-3 .
    [Google Scholar]
  14. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 2020; 5:(11):1403-1407. doi: 10.1038/s41564-020-0770-5 .
    [Google Scholar]
  15. European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. Available from https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants. Accessed August 2, 2021.
  16. Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020; 182:(5):1284–1294.e9.
    [Google Scholar]
  17. CDC. SARS-CoV-2 variant classifications and definitions. Available from https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed August 2, 2021.
    [Google Scholar]
  18. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Available from https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v2.full-text. Accessed July 29, 2021.
    [Google Scholar]
  19. Achaiah NC, Subbarajasetty SB, Shetty RM. R0 and Re of COVID-19: can We Predict when the Pandemic Outbreak will be Contained? Indian J Crit Care Med 2020; 24:(11):1125–1127. doi: 10.5005/jp-journals-10071-23649 .
    [Google Scholar]
  20. What we know about the SARS-CoV-2 Delta variant. Available from https://newsroom.unsw.edu.au/news/health/what-we-know-about-sars-cov-2-delta-variant. Accessed August 2, 2021. UNSW.
  21. Gani R, Leach S. Transmission potential of smallpox in contemporary populations. Nature 2001; 414:(6865):748–751. doi: 10.1038/414748a .
    [Google Scholar]
  22. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant [published online ahead of print, July 21 2021]. N Engl J Med 2021; 385:(7):585–594. doi: 10.1056/NEJMoa2108891 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2021.49
Loading
/content/journals/10.5339/qmj.2021.49
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error